{
    "info": {
        "nct_id": "NCT03193190",
        "official_title": "A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)",
        "inclusion_criteria": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Histologically or cytologically confirmed metastatic pancreatic ductal adenocarcinoma\n* For patients in Cohort 1: no prior systemic treatment for PDAC\n* For patients in Cohort 2: disease progression during administration of either 5-FU- or gemcitabine-based first-line chemotherapy\n* Life expectancy greater than or equal to 3 months\n* Availability of a representative tumor specimen that is suitable for determination of programmed death-ligand 1 (PD-L1) and/or additional biomarker status via central testing\n* Measurable disease (at least one target lesion) according to RECIST v1.1\n* Adequate hematologic and end-organ function test results\n* Tumor accessible for biopsy\n* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating eggs, as outlined for each specific treatment arm\n* For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as outlined for each specific treatment arm\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring drainage procedure (i.e., more than one time per month)\n* Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases\n* History of leptomeningeal disease\n* Active or history of autoimmune disease or immune deficiency\n* History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan\n* Positive human immunodeficiency (HIV) test at screening or at any time prior to screening\n* Active hepatitis B or C virus infection or active tuberculosis\n* Severe infection within 4 weeks prior to initiation of study treatment\n* Prior allogeneic stem cell or solid organ transplantation\n* History of malignancy other than pancreatic carcinoma within 2 years prior to screening, with the exception of those with a negligible risk of metastasis or death",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Histologically or cytologically confirmed metastatic pancreatic ductal adenocarcinoma",
            "criterions": [
                {
                    "exact_snippets": "Histologically or cytologically confirmed",
                    "criterion": "pancreatic ductal adenocarcinoma",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis confirmation method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "metastatic pancreatic ductal adenocarcinoma",
                    "criterion": "pancreatic ductal adenocarcinoma",
                    "requirements": [
                        {
                            "requirement_type": "disease stage",
                            "expected_value": "metastatic"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate hematologic and end-organ function test results",
            "criterions": [
                {
                    "exact_snippets": "Adequate hematologic ... function test results",
                    "criterion": "hematologic function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate ... end-organ function test results",
                    "criterion": "end-organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Availability of a representative tumor specimen that is suitable for determination of programmed death-ligand 1 (PD-L1) and/or additional biomarker status via central testing",
            "criterions": [
                {
                    "exact_snippets": "Availability of a representative tumor specimen",
                    "criterion": "tumor specimen",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "representativeness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "suitable for determination of programmed death-ligand 1 (PD-L1) and/or additional biomarker status via central testing",
                    "criterion": "tumor specimen suitability for biomarker testing",
                    "requirements": [
                        {
                            "requirement_type": "suitability for PD-L1 and/or additional biomarker status determination via central testing",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as outlined for each specific treatment arm",
            "criterions": [
                {
                    "exact_snippets": "For men: agreement to remain abstinent (refrain from heterosexual intercourse)",
                    "criterion": "sexual activity",
                    "requirements": [
                        {
                            "requirement_type": "abstinence from heterosexual intercourse",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "For men: ... or use contraceptive measures",
                    "criterion": "contraceptive use",
                    "requirements": [
                        {
                            "requirement_type": "use of contraception",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "For men: ... agreement to refrain from donating sperm",
                    "criterion": "sperm donation",
                    "requirements": [
                        {
                            "requirement_type": "refrain from donating sperm",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Life expectancy greater than or equal to 3 months",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy greater than or equal to 3 months",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For patients in Cohort 1: no prior systemic treatment for PDAC",
            "criterions": [
                {
                    "exact_snippets": "no prior systemic treatment for PDAC",
                    "criterion": "prior systemic treatment for PDAC",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating eggs, as outlined for each specific treatment arm",
            "criterions": [
                {
                    "exact_snippets": "For women of childbearing potential",
                    "criterion": "childbearing potential (female)",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures",
                    "criterion": "pregnancy prevention behavior",
                    "requirements": [
                        {
                            "requirement_type": "abstinence or contraception",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "agreement to refrain from donating eggs",
                    "criterion": "egg donation",
                    "requirements": [
                        {
                            "requirement_type": "donation",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For patients in Cohort 2: disease progression during administration of either 5-FU- or gemcitabine-based first-line chemotherapy",
            "criterions": [
                {
                    "exact_snippets": "disease progression during administration of either 5-FU- or gemcitabine-based first-line chemotherapy",
                    "criterion": "disease progression during first-line chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "chemotherapy regimen",
                            "expected_value": [
                                "5-FU-based",
                                "gemcitabine-based"
                            ]
                        },
                        {
                            "requirement_type": "line of therapy",
                            "expected_value": "first-line"
                        },
                        {
                            "requirement_type": "disease progression",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Tumor accessible for biopsy",
            "criterions": [
                {
                    "exact_snippets": "Tumor accessible for biopsy",
                    "criterion": "tumor",
                    "requirements": [
                        {
                            "requirement_type": "accessibility for biopsy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Measurable disease (at least one target lesion) according to RECIST v1.1",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease (at least one target lesion) according to RECIST v1.1",
                    "criterion": "measurable disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "target lesion"
                            }
                        },
                        {
                            "requirement_type": "assessment_criteria",
                            "expected_value": "RECIST v1.1"
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan",
            "criterions": [
                {
                    "exact_snippets": "History of idiopathic pulmonary fibrosis",
                    "criterion": "idiopathic pulmonary fibrosis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "organizing pneumonia",
                    "criterion": "organizing pneumonia",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "drug-induced pneumonitis",
                    "criterion": "drug-induced pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "idiopathic pneumonitis",
                    "criterion": "idiopathic pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "evidence of active pneumonitis on screening chest computed tomography (CT) scan",
                    "criterion": "active pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "evidence_on_CT_scan",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active or history of autoimmune disease or immune deficiency",
            "criterions": [
                {
                    "exact_snippets": "Active or history of autoimmune disease",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "activity or history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "immune deficiency",
                    "criterion": "immune deficiency",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior allogeneic stem cell or solid organ transplantation",
            "criterions": [
                {
                    "exact_snippets": "Prior allogeneic stem cell ... transplantation",
                    "criterion": "allogeneic stem cell transplantation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior ... solid organ transplantation",
                    "criterion": "solid organ transplantation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of malignancy other than pancreatic carcinoma within 2 years prior to screening, with the exception of those with a negligible risk of metastasis or death",
            "criterions": [
                {
                    "exact_snippets": "History of malignancy other than pancreatic carcinoma within 2 years prior to screening",
                    "criterion": "history of malignancy (other than pancreatic carcinoma)",
                    "requirements": [
                        {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "with the exception of those with a negligible risk of metastasis or death",
                    "criterion": "malignancy risk of metastasis or death",
                    "requirements": [
                        {
                            "requirement_type": "risk",
                            "expected_value": "negligible"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases",
            "criterions": [
                {
                    "exact_snippets": "Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases",
                    "criterion": "central nervous system (CNS) metastases",
                    "requirements": [
                        {
                            "requirement_type": "symptom status",
                            "expected_value": "symptomatic"
                        },
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "untreated"
                        },
                        {
                            "requirement_type": "progression status",
                            "expected_value": "actively progressing"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active hepatitis B or C virus infection or active tuberculosis",
            "criterions": [
                {
                    "exact_snippets": "Active hepatitis B or C virus infection",
                    "criterion": "hepatitis B virus infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Active hepatitis B or C virus infection",
                    "criterion": "hepatitis C virus infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "active tuberculosis",
                    "criterion": "tuberculosis",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of leptomeningeal disease",
            "criterions": [
                {
                    "exact_snippets": "History of leptomeningeal disease",
                    "criterion": "leptomeningeal disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring drainage procedure (i.e., more than one time per month)",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled pleural effusion ... requiring drainage procedure (i.e., more than one time per month)",
                    "criterion": "pleural effusion",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "drainage frequency",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "per month"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Uncontrolled ... pericardial effusion ... requiring drainage procedure (i.e., more than one time per month)",
                    "criterion": "pericardial effusion",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "drainage frequency",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "per month"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Uncontrolled ... ascites requiring drainage procedure (i.e., more than one time per month)",
                    "criterion": "ascites",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "drainage frequency",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "per month"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Positive human immunodeficiency (HIV) test at screening or at any time prior to screening",
            "criterions": [
                {
                    "exact_snippets": "Positive human immunodeficiency (HIV) test at screening or at any time prior to screening",
                    "criterion": "HIV test result",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "positive"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": [
                                "at screening",
                                "at any time prior to screening"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Severe infection within 4 weeks prior to initiation of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Severe infection within 4 weeks prior to initiation of study treatment",
                    "criterion": "severe infection",
                    "requirements": [
                        {
                            "requirement_type": "presence_within_timeframe",
                            "expected_value": "within 4 weeks prior to initiation of study treatment"
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}